决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies.
对肿瘤微环境认识的深入推动了免疫治疗策略的发展,例如CAR-T 细胞。
实体瘤CAR-T治疗受限于肿瘤浸润不足。本研究基于此前对人类细胞毒性淋巴细胞早期体内浸润实体瘤的认识,分析原发非小细胞肺癌正常组织、癌旁组织及肿瘤组织中的受体。结果发现CX3CL1-CX3CR1轴减弱会限制细胞毒性免疫细胞进入实体瘤,从而促进肿瘤逃逸。研究者在表达成熟NK 细胞受体NKG2D CAR的基础上进一步过表达CX3CR1,以增强CAR-T浸润。该构建体较对照活化T细胞及过表达IL-15的NKG2D CAR-T具有更高肿瘤浸润率。在肝癌模型中也表现出类似功能,提示该策略可能适用于其他实体瘤。
Advances in the understanding of the tumor microenvironment have led to development of immunotherapeutic strategies, such as chimeric antigen receptor T cells (CAR-Ts). However, despite success in blood malignancies, CAR-T therapies in solid tumors have been hampered by their restricted infiltration. Here, we used our understanding of early cytotoxic lymphocyte infiltration of human lymphocytes in solid tumors in vivo to investigate the receptors in normal, adjacent, and tumor tissues of primary non-small-cell lung cancer specimens. We found that CX3CL1-CX3CR1 reduction restricts cytotoxic cells from the solid-tumor bed, contributing to tumor escape. Based on this, we designed a CAR-T construct using the well-established natural killer group 2, member D (NKG2D) CAR-T expression together with overexpression of CX3CR1 to promote their infiltration. These CAR-Ts infiltrate tumors at higher rates than control-activated T cells or IL-15-overexpressing NKG2D CAR-Ts. This construct also had similar functionality in a liver-cancer model, demonstrating potential efficacy in other solid malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。